Phase 4
Completed N=38
Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
Source: ClinicalTrials.gov NCT02115581 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: Improvement in Left Ventricular Ejection Fraction — 42.1; 37.6 Percentage — p=0.267
Summary
This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Improvement in Left Ventricular Ejection Fraction |
42.1; 37.6 | 0.267 |
| PRIMARY Improvement in Left Ventricular Filling Abnormality |
59; 19 | 0.011 sig |
| SECONDARY Adverse Events |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Known cases of Idiopathic Dilated Cardiomyopathy (IDC)
- Those patients in whom heart failure medications were stable for at least 1 month
- More than 6 months aged
Exclusion Criteria
- Recent modification in medications
- Hemodynamic instability
- Congenital heart disease
- Metabolic heart disease
- Cardiac dysfunction resulting from abnormalities in other organs and those with an acquired cardiomyopathy
Data sourced from ClinicalTrials.gov (NCT02115581). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.